How I treat ADA deficiency
Open Access
- 22 October 2009
- journal article
- review article
- Published by American Society of Hematology in Blood
- Vol. 114 (17), 3524-3532
- https://doi.org/10.1182/blood-2009-06-189209
Abstract
Adenosine deaminase deficiency is a disorder of purine metabolism leading to severe combined immunodeficiency (ADA-SCID). Without treatment, the condition is fatal and requires early intervention. Haematopoietic stem cell transplantation is the major treatment for ADA-SCID, although survival following different donor sources varies considerably. Unlike other SCID forms, 2 other options are available for ADA-SCID: enzyme replacement therapy (ERT) with pegylated bovine ADA, and autologous haematopoietic stem cell gene therapy (GT). Due to the rarity of the condition, the lack of large scale outcome studies, and availability of different treatments, guidance on treatment strategies is limited. We have reviewed the currently available evidence and together with our experience of managing this condition propose a consensus management strategy. Matched sibling donor transplants represent a successful treatment option with high survival rates and excellent immune recovery. Mismatched parental donor transplants have a poor survival outcome and should be avoided unless other treatments are unavailable. ERT and GT both show excellent survival, and therefore the choice between ERT, MUD transplant, or GT is difficult and dependent on several factors, including accessibility to the different modalities, response of patients to long-term ERT, and the attitudes of physicians and parents to the short- and potential long-term risks associated with different treatments.Keywords
This publication has 50 references indexed in Scilit:
- Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patientsJCI Insight, 2008
- Neonatal bone marrow transplantation of ADA-deficient SCID mice results in immunologic reconstitution despite low levels of engraftment and an absence of selective donor T lymphoid expansionBlood, 2008
- Altered intracellular and extracellular signaling leads to impaired T-cell functions in ADA-SCID patientsBlood, 2008
- Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapyJCI Insight, 2007
- Prolonged pancytopenia in a gene therapy patient with ADA-deficient SCID and trisomy 8 mosaicism: a case reportBlood, 2006
- Clonal evidence for the transduction of CD34+ cells with lymphomyeloid differentiation potential and self-renewal capacity in the SCID-X1 gene therapy trialBlood, 2005
- Bilateral sensorineural deafness in adenosine deaminase-deficient severe combined immunodeficiencyThe Journal of Pediatrics, 2004
- Hepatic Dysfunction as a Complication of Adenosine Deaminase DeficiencyNew England Journal of Medicine, 1996
- Amelioration of Neurologic Abnormalities after Enzyme Replacement in Adenosine Deaminase DeficiencyNew England Journal of Medicine, 1980
- The chondro-osseous dysplasia of adenosine deaminase deficiency with severe combined immunodeficiencyThe Journal of Pediatrics, 1976